Paul Trippier, PhD

Dr. Trippier’s research is focused on small molecule drug discovery for cancer and neurodegenerative diseases. His lab employs synthetic medicinal chemistry, chemical biology and molecular pharmacology techniques to design, optimize and employ biologically active compounds as chemical probes to interrogate novel pathways relevant to human disease and as lead compounds for novel drug discovery.

Discoveries in the Trippier lab have led to the identification of the most potent and selective Aldo-keto reductase 1C3 (AKR1C3) inhibitor which shows significant effect to counter drug resistance in prostate cancer and leukemia; the most potent synthetic succinate dehydrogenase inhibitor yet described with significant anticancer activity; novel multi-targeted agents for neurodegenerative disease therapy; and potent activators of neurolysin for stroke therapy development. This research has been and is currently funded by the NCI, NINDS, various private foundations and the pharmaceutical industry.

• Vada Kinman Oldfield Award for Research in Alzheimer's Disease 2024
• Excellence in Mentoring Award 2023, UNMC Office of Postdoctoral Education
• Secretary of the ACS Division of Medicinal Chemistry
• Elected Fellow of the Royal Society of Chemistry
• UNMC Distinguished Scientist Award 2021
• Member, Early Career Editorial Advisory Board; Journal of Medicinal Chemistry
• Member, Scientific Advisory Board of ChemicalProbes.org
• Invited speaker; Early Career Investigators in Biological Chemistry, 254^th ACS National Meeting, Washington D.C